Drug Discovery

Alkahest has assembled a unique technology platform and plasma sample collections in order to elucidate changes in the plasma proteome in healthy aging and in age-related diseases. The Company has identified specific proteins or “chronokines” that increase in aging and age-related diseases, as well as proteins or chronokines that decrease in aging and age-related diseases. Chronokines that decrease in age-related diseases such as TIMP21 are candidates for replacement or supplementation, whereas chronokines that increase in age-related diseases such as CCL112 or B2M3 are candidates for inhibition or removal. The Company has characterized distinctive “signatures” or patterns of increasing or decreasing chronokines in healthy aging and certain age-related diseases. Alkahest’s product pipeline is based on the Company’s unique insights into aging and age-related diseases that have evolved from its technology platform.

  1. Castellano JM, et al. (2017) Human umbilical plasma proteins revitalize hippocampal function in aged mice. Nature 544:488–492
  2. Vileda SA, Wyss-Coray T (2013) The circulatory systemic environment as a modulator of neurogenesis in brain aging. Autoimmunity Reviews 12:674-677
  3. Smith LK, et al. (2015) Beta-2 microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nature Medicine 8:9320937